![](/images/graphics-bg.png)
Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease
المؤلفون المشاركون
Jesudason, Shilpanjali
Jalleh, Ryan
Basu, Gopal
Le Leu, Richard
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-11-04
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Background.
Hypocalcaemia is increasingly recognized as a complication of denosumab use in Chronic Kidney Disease (CKD) patients with osteoporosis.
Despite Therapeutic Goods Administration (TGA) notifications in 2013, we have subsequently encountered several cases of denosumab-induced hypocalcaemia, raising concern about lack of widespread awareness among prescribing practitioners.
Aims.
We reviewed the morbidity and healthcare intervention needs of CKD patients with hypocalcaemia attributed to denosumab.
Methods.
A retrospective case series of CKD patients with clinically significant hypocalcaemia after exposure to denosumab, encountered at the tertiary care referral hospital from December 2013 to February 2017, was undertaken.
Results.
Eight patients (52-85 years of age) with stage 4-5 CKD developed clinically significant hypocalcaemia (corrected calcium 1.45±0.21mmol/L) following denosumab therapy for osteoporosis.
Seven of the eight patients required inpatient management with three patients requiring intravenous calcium replacement and cardiac monitoring in a high dependency unit.
Our study also identified additional factors that could potentially contribute to hypocalcaemia such as lack of calcium supplementation, use of noncalcium based phosphate binders, absence of or use of lower doses of calcitriol supplementation, low vitamin D levels, concomitant treatment with loop diuretics, history of parathyroidectomy, or presence of acute medical illness.
Conclusion.
Multiple cases of severe hypocalcaemia in CKD patients following denosumab exposure were encountered after TGA warnings, resulting in considerable morbidity and intensive healthcare interventions in CKD patients.
We advocate greater awareness amongst the medical profession, careful consideration before using denosumab in CKD patients, and close follow-up after administration to prevent morbidity.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Jalleh, Ryan& Basu, Gopal& Le Leu, Richard& Jesudason, Shilpanjali. 2018. Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease. Case Reports in Nephrology،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1145239
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Jalleh, Ryan…[et al.]. Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease. Case Reports in Nephrology No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1145239
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Jalleh, Ryan& Basu, Gopal& Le Leu, Richard& Jesudason, Shilpanjali. Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease. Case Reports in Nephrology. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1145239
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1145239
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)